Investor Presentation Q1-Q3 2020
92
Investor presentation
First nine months of 2020
Rest of World at a glance
Diabetes trend
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Novo Nordisk®
Million
DKK
billion
30%
First nine months
2020
Sales
(mDKK)
Growth²
200
30%
I
150
50
40
100
202
30
155
WA Ug
70
Long-acting insulin³
1,554
8%
70
80%
Premix insulin4
1,862
11%
60
Fast-acting insulin 5
1,639
5%
32%1
GLP-1
60%
Human insulin
1,871
25%
Insulin
2%1
Total insulin
6,926
12%
40%
GLP-16
1,741
51%
Other Diabetes care?
499
(2%)
119
50
20
7%1
OAD
Diabetes care
9,166
17%
20%
Obesity care
10
771
7%
(SaxendaⓇ)
0
2019
0
0%
Diabetes & Obesity
9,937
16%
Aug
2030
2045
2015
Aug
2020
care
Population with diabetes
Diabetes growth rate
Biopharm³
3,467
5%
GLP-1 MS
-Insulin MS
OAD MS
Total
13,404
13%
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
International Diabetes Federation: Diabetes Atlas 1th Edition 2000 and Diabetes Atlas
9th Edition 2019
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of Aug 2020: Novo Nordisk 56%, Sanofi
24% and Eli Lilly 16%; Competitor GLP-1 value market shares, as of Aug 2020: Novo
Nordisk 42%, Eli Lilly 53% and AstraZeneca 4%
OAD: Oral anti-diabetic; MS: Market share; Source: IQVIA MAT, Aug 2020 value
figures
2 At constant exchange rates 3 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 4
Comprises NovoMix® and RyzodegⓇ: 5 Comprises NovoRapid®; 6 Comprises
VictozaⓇ and OzempicⓇ:7 Comprises Novo NormⓇ and needles;
8 Comprises primarily NovoSevenⓇ, Novo Eight® and NorditropinⓇView entire presentation